Clinical trials: Anxiety, Generalized
Anxiety Disorders,Generalized Anxiety Disorder
A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
This is a study in minors (7 to 17 years old) diagnosed with generalized anxiety disorder (GAD) and evaluated using standard questionnaires as having at least moderate severity of GAD.
- Trial name
- NCT03924323
- Testing
- Escitalopram
- Where
- 39 sites in United States
- Volunteers
- 273 people
- Sponsor
- AbbVie
Pain, Depression
Study Evaluating Rhapsody Registry in Patients With Depression and Anxiety
The purpose of this study is to assess the prevalence of Major Depression and/or Anxiety Disorder in patients consulting the General Practitioner with acute or chronic painful physical symptoms and to identify risk factors.
- Conditions
- Pain, Depression, Anxiety Disorder
- Trial name
- NCT00241397
- Where
- 91 sites in Belgium
- Volunteers
- 2,560 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Generalized Anxiety Disorder
CES for the Treatment of GAD in Young Adults
The purpose of this research study is to study cranial electrotherapy stimulation (CES) to determine its effects on symptoms of anxiety in people with generalized anxiety disorder (GAD) between the ages of 18 - 21 years of age.
- Trial name
- NCT06124014
- Testing
- At-Home Stimulation
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Electromedical Products International, Inc.
Generalized Anxiety Disorder
6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
This is an open-label, multi-site, 6-month study of an investigational compound in elderly outpatients, age 65 years old or above, to assess the long-term safety and tolerability of the compound in the treatment of elderly…
- Trial name
- NCT00738738
- Testing
- PD-0332334
- Where
- 2 sites in United States
- Sponsor
- Pfizer
Anxiety Disorders
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder
This study will examine duloxetine compared with placebo and an active comparator in the treatment of generalized anxiety disorder.
- Trial name
- NCT00122850
- Testing
- Duloxetine, venlafaxine
- Where
- 19 sites in United States
- Volunteers
- 480 people
- Sponsor
- Eli Lilly and Company
Anxiety Disorder, Anxiety Disorders
Study Of Generalized Anxiety Disorder
This study is designed to evaluate the efficacy and safety in Generalized Anxiety Disorder patients
- Trial name
- NCT00135525
- Testing
- Paroxetine
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder, Fibromyalgia
Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
The primary objective of this study is to provide duloxetine to investigators for the treatment of patients who have previously participated in neuroscience duloxetine clinical trials and for whom effective alternative therapy is…
- Conditions
- Major Depressive Disorder, Fibromyalgia, Diabetic Peripheral Neuropathic Pain, Generalized Anxiety Disorder
- Trial name
- NCT00071708
- Testing
- Duloxetine Hydrochloride
- Where
- 13 sites in Australia
- Sponsor
- Eli Lilly and Company
Generalized Anxiety Disorder
Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).
The primary objective of this study is to evaluate the efficacy of pregabalin as compared to placebo in the treatment of patients with general anxiety disorder (GAD).
- Trial name
- NCT00413010
- Testing
- pregabalin
- Where
- 68 sites in United States, Czechia and 6 more
- Volunteers
- 356 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Anxiety Disorders
Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325
The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
- Trial name
- NCT00807937
- Testing
- AZD7325, Lorazepam
- Where
- 51 sites in United States
- Volunteers
- 369 people
- Sponsor
- AstraZeneca
General Anxiety Disorder
Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Anxiety in Adolescents
Trial title: A Randomized, Double-blind Sham-controlled Clinical Trial to Evaluate The Efficacy of Electrical Vestibular Stimulation (VeNS), Compared to a Sham Control For The Management Of Anxiety in Adolescents - The Modius…
- Trial name
- NCT06956105
- Testing
- Modius Calm
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Neurovalens Ltd.
Anxiety Disorder
Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder
To evaluate the efficacy of a fixed dose of SR58611A (350mg q12) compared to placebo in patients with GeneralizedAnxiety Disorder (GAD) using escitalopram (10 mg qd) as positive control.
- Trial name
- LIBRA (NCT00252343)
- Testing
- SR58611A
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Sanofi
Generalized Anxiety Disorder
Randomized Trial of Adult Participants With Generalized Anxiety Disorder
The purpose of this study is to compare the efficacy of troriluzole versus placebo in participants with generalized anxiety disorder.
- Trial name
- NCT03829241
- Testing
- Troriluzole
- Where
- 53 sites in United States
- Volunteers
- 881 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Generalized Anxiety Disorder (GAD)
Device for Treating Generalized Anxiety
The goal of this clinical trial is to learn if treatment with the BTL-699-2 device (non-invasive repetitive transcranial magnetic stimulation) can decrease anxiety symptoms in adults (aged 22 years and older) diagnosed with…
- Trial name
- NCT07819773
- Testing
- EXOMIND (BTL-699-2) Active treatment
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- BTL Industries Ltd.
Generalized Anxiety Disorder
Empower Neuromodulation System - Pilot Study for Anxiety Treatment
This study evaluates the effects of peripheral nerve stimulation on anxiety levels in participants with Generalized Anxiety Disorder (GAD).
- Trial name
- NCT04901481
- Testing
- Empower Neuromodulation System
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Theranova, L.L.C.
Generalized Anxiety Disorder
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
The purpose of this study is to determine if treatment with a single and/or repeat dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
- Trial name
- NCT07489651
- Testing
- RE104 for Injection
- Where
- 28 sites in United States
- Volunteers
- 160 people
- Sponsor
- Reunion Neuroscience Inc
Social Anxiety Disorder
Efficacy of Quetiapine in Generalised Social Anxiety Disorder
This trial will explore the efficacy of quetiapine in Social Anxiety Disorder, generalized type. The following elements of response will be tested: number of responders to treatment, time to response, effect size as measured with…
- Trial name
- NCT00302770
- Testing
- quetiapine
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder
POC Study in Partially Responsive Generalized Anxiety Disorder
This study aims to evaluate whether PF-06372865 is safe and effective in the treatment of sub-optimally controlled symptoms of generalized anxiety disorder during two 4-week treatment periods using a Sequential Parallel…
- Trial name
- NCT02310568
- Testing
- PF-06372865.
- Where
- 47 sites in United States
- Volunteers
- 90 people
- Sponsor
- Pfizer
Anxiety Disorders
A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)
The study will look at the effect of MK0777on reducing anxiety in subjects with general anxiety disorder. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time.
- Trial name
- NCT00543920
- Testing
- MK0777
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Generalized Anxiety Disorder
Echinacea Angustifolia (AnxioCalm) in Anxiety
This study evaluates whether Echinacea angustifolia (AnxioCalm) is a safe and effective treatment for mild to moderate Generalized Anxiety Disorder (GAD) symptoms.
- Trial name
- NCT03463018
- Testing
- Echinacea angustifolia
- Where
- Georgia
- Volunteers
- 100 people
- Sponsor
- EuroPharma, Inc.
Generalized Anxiety
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with generalized anxiety disorder.
- Trial name
- NCT00417118
- Testing
- Saredutant, Escitalopram
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 365 people
- Sponsor
- Sanofi